- Home
- CHRS vs NKSH Comparison
CHRS vs NKSH Comparison
Compare CHRS & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- NKSH
- Stock Information
- Founded
- CHRS 2010
- NKSH 1891
- Country
- CHRS United States
- NKSH United States
- Employees
- CHRS N/A
- NKSH N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- NKSH Major Banks
- Sector
- CHRS Health Care
- NKSH Finance
- Exchange
- CHRS Nasdaq
- NKSH Nasdaq
- Market Cap
- CHRS 84.2M
- NKSH 163.0M
- IPO Year
- CHRS 2014
- NKSH N/A
- Fundamental
- Price
- CHRS $0.82
- NKSH $29.84
- Analyst Decision
- CHRS Buy
- NKSH Strong Buy
- Analyst Count
- CHRS 3
- NKSH 1
- Target Price
- CHRS $4.68
- NKSH $38.00
- AVG Volume (30 Days)
- CHRS 1.3M
- NKSH 18.2K
- Earning Date
- CHRS 08-07-2025
- NKSH 08-13-2025
- Dividend Yield
- CHRS N/A
- NKSH 5.06%
- EPS Growth
- CHRS N/A
- NKSH N/A
- EPS
- CHRS N/A
- NKSH 1.38
- Revenue
- CHRS $272,251,000.00
- NKSH $46,211,000.00
- Revenue This Year
- CHRS N/A
- NKSH N/A
- Revenue Next Year
- CHRS $106.56
- NKSH $5.93
- P/E Ratio
- CHRS $1.90
- NKSH $21.57
- Revenue Growth
- CHRS 19.87
- NKSH 2.21
- 52 Week Low
- CHRS $0.66
- NKSH $23.75
- 52 Week High
- CHRS $2.43
- NKSH $33.37
- Technical
- Relative Strength Index (RSI)
- CHRS 53.65
- NKSH 73.23
- Support Level
- CHRS $0.72
- NKSH $27.01
- Resistance Level
- CHRS $0.77
- NKSH $27.88
- Average True Range (ATR)
- CHRS 0.04
- NKSH 0.77
- MACD
- CHRS 0.01
- NKSH 0.37
- Stochastic Oscillator
- CHRS 91.74
- NKSH 98.84
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.